Anishiya Abrol > Hogan Lovells US LLP > Washington DC, United States > Lawyer Profile

Hogan Lovells US LLP
United States

Work Department

Intellectual Property




Anishiya Abrol supports companies in their development and commercialization of cutting-edge medical therapies and tools. She advises on and negotiates a variety of strategic transactions from collaborations to in-licensing and out-licensing to maximize intellectual property assets, and then assists the company in implementing and integrating the new assets.

Anishiya has been seconded to multiple life sciences companies. She knows the issues facing in-house counsel and works closely with members of the firm’s Regulatory and Privacy Practice groups to provide integrated and practical advice.

Anishiya’s practice encompasses the full life sciences life cycle, from the discovery in the lab to dispensing to a patient. She has an undergraduate science degree, and her curious nature draws her towards early stage research and development transactions and activities, including clinical trial agreements, material transfer agreements, contract research organization (CRO) agreements, core lab agreements, sponsored research, grants, and technology transfers, both domestically and internationally. Recognizing though that a therapy’s primary value lies in the hands of patients, she assists commercialization efforts with support on distribution agreements, specialty pharmacy agreements, co-promotion agreements, authorized generic agreements, out-licensing arrangements, and other similar commercial activities.




Chair, Wills for Heroes Program, Virginia Bar Association (2008-2013)
Member, American Health Law Association
Member, Virginia Bar Association


J.D., George Mason University School of Law, magna cum laude, 2004
B.A. Biology, University of Virginia, 1997
B.A. History, University of Virginia, 1997

Lawyer Rankings

United States > Industry focus > Healthcare: life sciences

(Next Generation Partners)

Anishiya AbrolHogan Lovells US LLP

Hogan Lovells US LLP ‘s national life sciences practice has a strong reputation for M&A, financing transactions and large-scale commercial deals. It also stands out for its dedicated regulatory offering and its experience in IP litigation and pharmaceutical and medical device product liability proceedings. Its Washington DC-based regulatory team was recently strengthened by the arrival of Jonathan Wasserman, former associate general counsel at Bristol Myers Squibb.  It is also highly commended for its Washington DC based FDA and healthcare regulatory team. Contacts in this space include Philip Katz, who leads the group’s pharmaceutical work; Randy Prebula, head of medical devices; Jonathan Kahan and David Fox, who focus on FDA matters; and Anishiya Abrol, a contact for commercial and licensing transactions. The service group is jointly led by Steve Abrams and Lynn Mehler in Philadelphia and Washington DC, respectively. Asher Rubin and Adriana Tibbitts joined Sidley Austin LLP in January 2021; Suzanne Filippi left for Morgan, Lewis & Bockius LLP in April, and Adam Golden left for Freshfields Bruckhaus Deringer LLP in May.